Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book

IJ Pharmaceutical Research

homeHome
play_arrowCurrent Issueformat_list_bulletedAll Issuesformat_indent_increaseIn Presscheck_boxAccepted Manuscripts
searchSearchqr_codeInstructions
bookmarkJournal InformationgroupsEditors & BoardsshareIndexing and Listing Sourceswaterfall_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementassignment_indReviewer and AE Registration FormemailSupportphoneContact Us
menuAPC
Authors GuideSubmit Manuscript

Outlines

https://doi.org/10.22037/ijpr.2016.1911

Novel Thiazolidinone-Azole Hybrids: Design, Synthesis and Antimycobacterial Activity Studies

Author(s):
Barbaros ErogluBarbaros Eroglua, Keriman Ozadali-SariKeriman Ozadali-Saria,*, Oya Unsal-TanOya Unsal-Tana, Sriram DharmarajanSriram Dharmarajanb, Perumal YogeeswariPerumal Yogeeswarib, Ayla BalkanAyla Balkana
aDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
bMedicinal Chemistry & Antimycobacterial Research Laboratory, Pharmacy Group, Birla Institute of Technology & Science – Pilani, Hyderabad Campus, Jawahar Nagar, Hyderabad 500 078, Andhra Pradesh, India.
IJ Pharmaceutical Research:Vol. 15, issue 4; 783-790
Published online:Oct 31, 2016
Article type:Original Article
Received:Dec 31, 2014
Accepted:Apr 30, 2015
How to Cite:Eroglu B, Ozadali-Sari K, Unsal-Tan O, Dharmarajan S, Yogeeswari P, et al. Novel Thiazolidinone-Azole Hybrids: Design, Synthesis and Antimycobacterial Activity Studies. Iran J Pharm Res. 2016;15(4):e125237. doi: https://doi.org/10.22037/ijpr.2016.1911

Abstract

Keywords
Thiazolidin-4-one
Triazole
Imidazole
Antimycobacterial activity

Introduction

Tuberculosis (TB) is one of the most common infectious diseases known to man. According to the WHO report in 2012, there were almost 9 million new cases of tuberculosis and 1.4 million tuberculosis deaths (1). The problems with current TB treatment are complex and include: a prolonged standard course regimen of six months, which often result in patient noncompliance; emergency of extremely drug-resistant tuberculosis (XDR-TB) strains; lack of effective drugs against the latent state (2-4). Therefore, there is an urgent need for antitubercular agents with improved properties such as enhanced activity against MDR strains, reduced toxicity, shortened duration of treatment.
Thiazolidin-4-one is an important scaffold known to be associated with several biological activities. It is known that (-) 2-(5-carboxypentyl)thiazolidin-4-one (actithiazic acid) isolated from the culture broth of a strain of streptomyces has antimycobacterial activity (5). This discovery has prompted researchers to focus on new thiazolidin-4-one derivatives as potential antimycobacterial agents (6-10). On the other hand, it has been extensively reported that many structurally diverse compounds having azole moieties such as imidazole (11-14), triazole (15-17), thiazole (18, 19), oxazole (20), pyrazole (21, 22), isoxazole (23), oxadiazole (24) showed antimycobacterial activity. In recent years, one of the important strategies used in antitubercular drug development studies is hybridization of the biologically active structures. Considering this strategy, it was reported to achieve a highly active molecule by hybridization of thiazolidin-4-one ring with various active structures (25).
These facts have led us to study on thiazolidinone-azole hybrid compounds which are expected to show antitubercular activity.

Experimental

Chemistry
Melting points were determined with a Thomas-Hoover Capillary Melting Point Apparatus (Philadelphia, PA, USA) and are uncorrected. ATR-FTIR spectra were obtained using the MIRacle ATR accessory (Pike technologies) in conjunction with a Spectrum BX FTIR spectrometer (Perkin Elmer) and were reported in cm-1. The 1H NMR (400 MHz) spectra (DMSO-d6) were recorded on a Varian Mercury 400 FT NMR spectrophotometer (Varian Inc, Palo Alto, CA, USA) using TMS as an internal reference (Chemical shift represented in δ ppm).The ESI-MS spectra were measured on a micromass ZQ-4000 single quadruple mass spectrometer. Elemental analyses (C, H, N) were performed on Leco CHNS 932 analyzer (USA).
General procedure for the preparation of Schiff bases 2a-b and hydrazones 3a-b
Equimolar amounts of an appropriate benzaldehyde and anilin/phenylhydrazine were refluxed in methanol in presence of acetic acid (1 drop) as a catalytic reagent for 4 h. The solvent was evaporated and the crude mixture was used without any purification in the next step.
General procedure for the preparation of 3-phenyl-2-[4-(1H-1,2,4-triazol/imidazol-1-yl)phenyl]-1,3-thiazolidin-4-ones 4a-b and 3-(phenylamino)-2-[4-(1H-1,2,4-triazol/imidazol-1-yl)phenyl]-1,3-thiazolidin-4-ones 5a-b
A mixture of Schiff bases or hydrazones 2a-b or 3a-b (1 mmol) and excess of mercaptoacetic acid (1 mL) was heated at 60-80 ºC until the reaction was completed. Ethyl acetate (5 mL) was added, the organic layer was washed with saturated NaHCO3 (3x20 mL), water (1x10 mL), dried with Na2SO4 and concentrated to give an oily residue. The oily residue was purified by column chromatography on silica gel using hexane-ethyl acetate as eluent (3:7).
3-phenyl-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin-4-one 4a
53% yield, mp 176-8 οC. 1H NMR (DMSO-d6, 400 MHz); δ 9.25 (1H; s; triazole), 8.21 (1H; s; triazole), 7.77 (2H; d; Ar-H3‴ and H5‴ J: 8.4 Hz), 7.60 (2H; d; Ar-H2‴ and H6‴ J: 8.4 Hz), 7.36-7.28 (4H; m; Ar-H2ꞌ, H3ꞌ, H5ꞌ and H6ꞌ), 7.16-7.14 (1H; m; Ar-H4ꞌ), 6.61 (1H; s; thiazol., H2), 4.08 (1H; dd; thiazol., H5a, J: 1.6 Hz, J: 15.6 Hz), 3.92 (1H; d; thiazol., H5b, J: 15.6 Hz). IR; cm-1 1674 (C=O). ESI-MS (m/z); 345 [M+Na]+, 323 [M+H]+. Anal. Calcd. for C17H14N4OS: C, 63.34; H, 4.38; N, 17.38; S, 9.94. Found: C, 62.28; H, 4.45; N, 17.60; S, 9.62.
3-phenyl-2-[4-(1H-imidazol-1-yl)phenyl]-1,3-thiazolidin-4-one 4b
47% yield, mp 75-77 οC. 1H NMR (DMSO-d6, 400 MHz); δ 8.22 (1H; s; imidazole), 7.71 (1H; s; imidazole), 7.57-7.52 (4H; m; Ar-H2‴, H3‴, H5‴ and H6‴), 7.36-7.28 (4H; m; Ar-H2ꞌ, H3ꞌ, H5ꞌ and H6ꞌ), 7.17-7.13 (1H; m; Ar-H4ꞌ), 7.07 (1H; s; imidazole), 6.60 (1H; s; thiazol., H2), 4.07 (1H; dd; thiazol., H5a, J: 1.2 Hz, J: 15.6 Hz), 3.90 (1H; d; thiazol., H5b, J: 15.6 Hz). IR; cm-1 1681 (C=O). ESI-MS (m/z); 344 [M+Na]+, 322 [M+H]+. Anal. Calcd. for C18H15N3OS: C, 67.27; H, 4.70; N, 13.07; S, 9.98. Found: C, 62.48; H, 4.57; N, 13.43; S, 10.08.
3-(phenylamino)-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin-4-one 5a
48% yield, mp 228-30 οC (dec.).1H NMR (DMSO-d6, 400 MHz); δ 9.32 (1H; s; triazole), 8.25 (1H; s; triazole), 8.22 (1H; s; NH), 7.88 (2H; d; Ar-H3‴ and H5‴ J: 8.4 Hz), 7.60 (2H; d; Ar-H2‴ and H6‴, J: 8.4 Hz), 7.16 (2H; t; Ar-H3ꞌ and H5ꞌ), 6.75 (1H; t; Ar-H4ꞌ), 6.67 (2H; d; Ar-H2ꞌ and H6ꞌ, J: 7.6 Hz), 5.95 (1H; d; thiazol., H2, J: 1.2 Hz), 3.98 (1H; dd; thiazol., H5a, J: 1.6 Hz, J: 15.6 Hz), 3.79 (1H; d; thiazol., H5b, J: 15.6 Hz). IR; cm-1 3220 (NH), 1696 (C=O). ESI-MS (m/z); 360 [M+Na]+, 338 [M+H]+. Anal. Calcd. for C17H15N5OS: C, 60.52; H, 4.48; N, 20.76; S, 9.50. Found: C, 60.31; H, 4.61; N, 20.54; S, 9.65.
3-(phenylamino)-2-[4-(1H-imidazol-1-yl)phenyl]-1,3-thiazolidin-4-one 5b
45% yield, mp 163-4 οC.1H NMR (DMSO-d6, 400 MHz); δ 8.28 (1H; s; imidazole), 8.22 (1H; s; NH), 7.77 (1H; s; imidazole), 7.66 (2H; d; Ar-H3‴ and H5‴ J: 8.8 Hz), 7.54 (2H; d; Ar-H2‴and H6‴, J: 8.8 Hz), 7.16 (2H; t; Ar-H3ꞌ and H5ꞌ), 7.11 (1H; s; imidazole), 6.75 (1H; t; Ar-H4ꞌ), 6.67 (2H; d; Ar-H2ꞌ and H6ꞌ, J: 8.8 Hz), 5.94 (1H; d; thiazol., H2, J: 1.6 Hz), 3.97 (1H; dd; thiazol., H5a, J: 1.6 Hz, J: 15.6 Hz), 3.79 (1H; d; thiazol., H5b, J:15.6 Hz). IR; cm-1 3170 (NH), 1681 (C=O). ESI-MS (m/z); 359 [M+Na]+, 337 [M+H]+. Anal. Calcd. for C18H16N4OS: C, 64.27; H, 4.79; N, 16.65; S, 9.53. Found: C, 64.47; H, 4.58; N, 16.83; S, 9.76.
General procedure for the preparation of 5-benzylidene/substitutedbenzylidene-3-(phenylamino)-2-[4-(1H-1,2,4-triazol/imidazol-1-yl)phenyl]-1,3-thiazolidin-4-ones 6-13
A mixture of 3-(phenylamino)-2-[4-(1H-1,2,4-triazol/imidazol-1-yl)phenyl]-1,3-thiazolidin-4-ones 5a-b (10 mmol) and 4-nonsubstituted/substitutedbenzaldehyde (10 mmol) was refluxed in 30 mL of ethanol in the presence of potassium hydroxide (15 mmol) for 8 h. The solvent was evaporated under reduced pressure and obtained oily residue was crystallized from appropriate solvent.
5-Benzylidene-3-(phenylamino)-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin
-4-one 6
38% yield, mp 156-7 οC.1H NMR (DMSO-d6, 400 MHz); δ 9.29 (1H; s; triazole), 8.46 (1H; s; NH), 8.22 (1H; s; triazole), 7.88 ( 2H; d; Ar-H2″and H6″ J: 8.4 Hz), 7.59 (2H; d; Ar-H3‴ and H5‴ J: 8.4 Hz), 7.56 (2H; d; Ar-H3″ and H5″J: 7.2 Hz), 7.51 (1H; s; CH=), 7.46 (2H; d; Ar-H2‴and H6‴ J: 8.4 Hz), 7.35 (1H; t; Ar-H4″), 7.15 (2H; t; Ar-H3ꞌ and H5ꞌ), 6.75 (1H; t; Ar-H4ꞌ), 6.65 (2H; d; Ar-H2ꞌ and H6ꞌJ: 8.0 Hz), 6.33 (1H; s; CH). IR; cm-1 3266 (NH), 1676 (C=O). ESI-MS (m/z); 448 [M+Na]+, 426 [M+H]+. Anal. Calcd. for C24H19N5OS: C, 67.74; H, 4.50; N, 16.46; S, 7.53. Found: C, 67.37; H, 4.54; N, 16.05; S, 6.81.
5-(4-Bromobenzylidene)-3-(phenylamino)-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin-4-one 7
57% yield, mp 192-3 οC.1H NMR (DMSO-d6, 400 MHz); δ 9.30 (1H; s; triazole), 8.50 (1H; s; NH), 8.23 (1H; s; triazole), 7.88 ( 2H; d; Ar-H2″ and H6″, J: 8.4 Hz), 7.65 (2H; d; Ar-H3‴ and H5‴ , J: 8.4 Hz), 7.59 (2H; d; Ar-H3″ and H5″, J: 8.4 Hz), 7.51 (2H; d; Ar-H2‴ and H6‴ , J: 8.4 Hz), 7.48 (1H; s; CH=), 7.15 (2H; t; Ar-H3ꞌand H5ꞌ), 6.75 (1H; t; Ar-H4ꞌ), 6.44 (2H; d; Ar-H2ꞌ and H6ꞌ, J: 7.6 Hz), 6.35 (1H; s; CH). IR; cm-1 3266 (NH), 1681 (C=O). ESI-MS (m/z); 544 [M+K+2]+, 528 [M+Na+2]+. Anal. Calcd. for C24H18BrN5OS.1 H2O: C, 55.18; H, 3.86; N, 13.41; S, 6.14. Found: C, 54.84; H, 3.73; N, 13.41; S, 6.64.
5-(4-Methylbenzylidene)-3-(phenylamino)-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin-4-one 8
29% yield, mp 161-2 οC.1H NMR (DMSO-d6, 400 MHz); δ 9.31 (1H; s; triazole), 8.48 (1H; s; NH), 8.24 (1H; s; triazole), 7.89 ( 2H; d; Ar-H2″ and H6″ , J: 7.2 Hz), 7.59 (2H; d; Ar-H3‴ and H5‴ , J: 7.6 Hz), 7.48 (1H; s; CH=), 7.46 (2H; d; Ar-H3″ and H5″ , J: 8.4 Hz), 7.28 (2H; d; Ar-H2‴ and H6‴ , J: 8.4 Hz), 7.15 (2H; t; Ar-H3ꞌ and H5ꞌ), 6.76 (1H; t; H4ꞌ), 6.66 (2H; d; Ar-H2ꞌ and H6ꞌ, J: 8.0 Hz), 6.33 (1H; s; CH), 3.34 (3H; s; CH3). IR; cm-1 3175 (NH), 1683 (C=O). ESI-MS (m/z); 478 [M+K]+, 462 [M+Na]+, 440 [M+H]+. Anal. Calcd. for C25H21N5OS.1/2 H2O: C, 66.94; H, 4.94; N, 15.61; S, 7.15. Found: C, 67.13; H, 4.64; N, 15.69; S, 7.28.
5-(4-Chlorobenzylidene)-3-(phenylamino)-2-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-thiazolidin-4-one 9
43% yield, mp 163-4 οC.1H NMR (DMSO-d6, 400 MHz); δ 9.29 (1H; s; triazole), 8.47 (1H; s; NH), 8.22 (1H; s; triazole), 7.88 (2H; d; Ar-H2″ and H6″ , J: 8.4 Hz), 7.65 (2H; d; Ar-H3‴ and H5‴, J: 8.4 Hz), 7.59 (2H; d; Ar-H3″ and H5″ , J: 8.4 Hz), 7.51 (2H; d; Ar-H2‴ and H6‴, J: 8.4 Hz), 7.48 (1H; s; CH=), 7.15 (2H; t; Ar-H3ꞌ and H5ꞌ), 6.75 (1H; t; Ar-H4ꞌ), 6.65 (2H; d; Ar-H2ꞌ and H6ꞌ, J: 7.2 Hz), 6.35 (1H; s; CH). IR; cm-1 3268 (NH), 1676 (C=O). ESI-MS (m/z); 500 [M+K+2]+, 482 [M+Na+2]+. Anal. Calcd. for C24H18ClN5OS.1/2 H2O: C, 61.47; H, 4.08; N, 14.93; S, 6.84. Found: C, 61.94; H, 3.99; N, 15.22; S, 6.82.
5-Benzylidene-3-(phenylamino)-2-[4-(1H-imidazol-1-y)phenyl]-1,3-thiazolidin-4-one 10
41% yield, mp 189-90 οC.1H NMR (DMSO-d6, 400 MHz); δ 8.48 (1H; s; NH), 8.26 (1H; s; imidazole), 7.74 (1H; s; imidazole), 7.68 ( 2H; d; Ar-H2″ and H6″, J: 8.4 Hz), 7.57-7.45 (7H; m; CH=, Ar-H2‴, H3‴, H5‴, H6‴, H3″ and H5″), 7.36 (1H; t; Ar-H4″), 7.18 (2H; t; Ar-H3ꞌ and H5ꞌ , 7.09 (1H; s; imidazole), 6.76 (1H; t; Ar-H4ꞌ ), 6.66 (2H; d; Ar-H2ꞌ and H6ꞌ , J: 8.0 Hz), 6.33 (1H; s; CH). IR; cm-1 3288 (NH), 1698 (C=O). ESI-MS (m/z); 447 [M+Na]+, 425 [M+H]+. Anal. Calcd. for C25H20N4OS: C, 70.73; H, 4.75; N, 13.20; S, 7.55. Found: C, 70.67; H, 4.99; N, 13.72; S, 7.43.
5-(4-Bromobenzylidene)-3-(phenylamino)-2-[4-(1H-imidazol-1-y)phenyl]-1,3-thiazolidin-4-one 11
61% yield, mp 223-4 οC.1H NMR (DMSO-d6, 400 MHz); δ 8.62 (1H; s; NH), 8.53 (1H; s; imidazole), 7.89 (1H; s; imidazole), 7.74 ( 2H; d; Ar-H2″ and H6″, J: 8.4 Hz), 7.68 (2H; d; Ar-H3‴ and H5‴, J: 8.4 Hz), 7.59 (2H; d; Ar-H3″ and H5″, J: 8.8 Hz), 7.53 (2H; d; Ar-H2‴ and H6‴, J: 9.2 Hz), 7.51 (1H; s; CH=), 7.31 (1H; s; imidazole), 7.18 (2H; t; Ar-H3ꞌ and H5ꞌ), 6.78 (1H; t; Ar-H4ꞌ), 6.68 (2H; d; Ar-H2ꞌ and H6ꞌ, J: 8.0 Hz), 6.38 (1H; s; CH). IR; cm-1 3266 (NH), 1696 (C=O). ESI-MS (m/z); 527 [M+Na+2]+, 505 [M+H+2]+. Anal. Calcd. for C25H19BrN4OS.3 H2O: C, 53.86; H, 4.52; N, 10.05; S, 5.75. Found: C, 54.00; H, 4.12; N, 10.43; S, 5.85.
5-(4-Methylbenzylidene)-3-(phenylamino)-2-[4-(1H-imidazol-1-y)phenyl]-1,3-thiazolidin-4-one 12
47% yield, mp 215-6 οC.1H NMR (DMSO-d6, 400 MHz); δ 8.47 (1H; s; NH), 8.23
(1H; s; imidazole), 7.75 (1H; s; imidazole), 7.70 ( 2H; d; Ar-H2″ and H6″, J: 8.4 Hz),
7.55 (2H; d; Ar-H3‴ and H5‴, J: 8.4 Hz), 7.49 (1H; s; CH=), 7.47 (2H; d; Ar-H3″ and H5″,
J: 8.0 Hz), 7.29 (2H; d; Ar-H2‴ and H6‴, J: 8.4 Hz), 7.18 (2H; t; Ar-H3ꞌ and H5ꞌ), 7.11 (1H; s; imidazole), 6.77 (1H; t; Ar-H4ꞌ),6.68 (2H; d; Ar-H2ꞌ and H6ꞌ, J: 8.0 Hz), 6.32 (1H; s; CH), 3.34 (3H; s; CH3). IR; cm-1 3288 (NH), 1695 (C=O). ESI-MS (m/z); 477 [M+K]+, 439 [M+H]+. Anal. Calcd. for C26H22N4OS.2 H2O: C, 65.80; H, 5.52; N, 11.81; S, 6.76. Found: C, 65.25; H, 5.21; N, 11.73; S, 6.74.
5-(4-Chlorobenzylidene)-3-(phenylamino)-2-[4-(1H-imidazol-1-y)phenyl]-1,3-thiazolidin-4-one 13
53% yield, mp 217-8 οC.1H NMR (DMSO-d6, 400 MHz); δ 8.51 (1H; s; NH), 8.28 (1H; s; imidazole), 7.77 (1H; s; imidazole), 7.74 ( 2H; d; Ar-H2″ and H6″, J: 8.4 Hz), 7.68 (2H; d; Ar-H3‴ and H5‴ , J: 8.4 Hz), 7.59 (2H; d; Ar-H3″ and H5″, J: 8.8 Hz), 7.53 (2H; d; Ar-H2‴ and H6‴ , J: 9.2 Hz), 7.51 (1H; s; CH=), 7.18 (2H; t; Ar-H3ꞌ and H5ꞌ ), 7.11 (1H; s; imidazole), 6.78 (1H; t; Ar-H4ꞌ ), 6.68 (2H; d; Ar-H2ꞌ and H6ꞌ , J: 8.0 Hz), 6.36 (1H; s; CH). IR; cm-1 3268 (NH), 1697 (C=O). ESI-MS (m/z); 483 [M+Na+2]+, 461 [M+H+2]+. Anal. Calcd. for C25H19ClN4OS.1/2 H2O: C, 64.16; H, 4.31; N, 11.97; S, 6.85. Found: C, 64.27; H, 5.02; N, 11.21; S, 6.51.
Antimycobacterial Activity Assay
The target compounds were tested for their antimycobacterial activity in vitro against M. tuberculosis H37Rv using the microplate alamar blue assay (MABA) method (27) in duplicate. Isoniazid, rifampin, ethambutol and ciprofloxacin were used as positive and DMSO as negative control. Compound stock solutions were prepared in DMSO. Sterile deionized water (200 μL) was added to all outer-perimeter wells of sterile 96-well plates to minimize evaporation of the medium in the test wells during incubation. The wells received 100 μL of Middlebrook 7H9GC broth and two fold serial dilutions of the target compounds/positive controls were prepared in a volume of 100 μL directly on the plate. 100 μL of MTB inoculum was added to the wells. The plates were sealed with parafilm and were incubated at 37 °C for five days. 50 μL of a freshly prepared 1:1 mixture of Alamar Blue (Accumed International, Westlake, Ohio) reagent and 10% Tween 80 was added to the plates and incubated at 37 °C for 24 h. A blue colour in the well was interpreted as no growth, and a pink colour was scored as growth. The MIC was determined as the lowest drug concentration which prevented a colour change from blue to pink. MICs of the compounds were reported in Table 1.
Conflict of Interest
We declare that we have no conflict of interest with respect to this study.

Results and Discussion

Chemistry
The starting compounds, 4-(1H-1,2,4-triazol/imidazol-1-yl)benzaldehydes 1a-b were synthesized in accordance with the method described in the literature (26). The intermediate compounds, Schiff bases and hydrazones (2a-b and 3a-b), were obtained by condensation of 1a-b with anilin or phenylhydrazine respectively. Reaction of 2a-b and 3a-b with mercaptoacetic acid yielded the thiazolidin-4-ones 4a-b and 5a-b (Figure 1). Compounds 6-13 were gained by treatment of 5a-b with appropriate benzaldehydes according to Knoevenagel condensation as outlined in Figure 2. The structures of the target compounds (4a-b, 5a-b and 6-13) were confirmed by IR, 1H NMR, mass spectrometry and elemental analysis.
Synthesis of 4a-b and 5a-b. Reagents and conditions: (i) aniline/phenylhydrazine, CH<sub>3</sub>COOH, methanol, reflux; (ii) mercaptoacetic acid, 60 ºC
Figure 1

Synthesis of 4a-b and 5a-b. Reagents and conditions: (i) aniline/phenylhydrazine, CH3COOH, methanol, reflux; (ii) mercaptoacetic acid, 60 ºC

Synthesis of 6-13. Reagent and condition: (i) appropriate benzaldehyde, KOH, ethanol, reflux
Figure 2

Synthesis of 6-13. Reagent and condition: (i) appropriate benzaldehyde, KOH, ethanol, reflux

Table 1Antimycobacterial activities of 4a-b, 5a-b and 6-13
In the IR spectra of compound 4a-b and 5a-b, the presence of the C=O stretching bands at around 1680 cm-1 indicated the thiazolidin-4-one ring closure. In the 1H NMR spectra of these compounds, the signals of nonequivalence methylenic protons of the thiazolidin-4-one ring were observed as two doublets at around 4.0 ppm (HA) and as doublet at around 3.9 ppm (HB) because of geminal (JAB of 15.6 Hz) and long range coupling (~JAx of 1.6 Hz) with C2 proton. Furthermore, the signal of the C2 proton of the thiazolidin-4-one ring was seen as singlet or doublet at around 6.0 ppm. In the 1H NMR spectra of 6-13, disappearance of the signals of methylenic protons and formation of a new signal at around 7.5 ppm proved benzylidene substitution to the thiazolidin-4-one ring. In the mass spectra, all compounds displayed molecular ion peaks which confirmed their molecular weight.
Antimycobacterial Activity
The target compounds (4a-b, 5a-b and 6-13) were evaluated for their antimycobacterial activity in-vitro against Mycobacterium tuberculosis H37Rv using the microplate alamar blue assay method (27) in duplicate. The results of the antimycobacterial activity (MIC values) were reported in Table 1.
When Table 1. were examined, it was seen that introduction of phenylamino group (5a with MIC of 74.18 μM and 5b with MIC of 37.20 μM) instead of phenyl group (4a with MIC of 77.64 μM and 4b with MIC of 155.76 μM) to 3th position of thiazolidin-4-one ring contributed to the activity, although this contribution was very limited for triazole substituted derivatives.
These results led us to focus on 3-(phenylamino)-1,3-thiazolidin-4-ones. As a continuation of our study, we condensed several benzaldehydes to obtain 5-(substitutedbenzylidene)-3-(phenylamino)-1,3-thiazolidin-4-ones (6-13). When we compared the activity results of 5a and 5b with 6-9 and 10-13 respectively, it was observed that benzylidene substitution to the 3-(phenylamino)-1,3-thiazolidin-4-ones enhanced the activity (except 11). However 12 (MIC: 14.27 μM) was the most active derivative in this series, introducing the substituents at the 4th position of the benzylidene ring decreased the activity in generally. According to the activity results of 6 and 10 (with MIC of 14.70 and 14.74 μM respectively), it can be assumed that non-substitutedbenzylidene structure is a favorable moiety for the activity. Comparing the compounds bearing triazole moiety (6-9) with that of imidazole analogues (10-13), it was seen that the type of the azole ring did not cause any remarkable difference on the activity except methyl substituted derivatives (8 with MIC of 56.94 μM and 12 with MIC of 14.74 μM). Furthermore, none of the compounds in the series were found as active as standard compounds (Table 1).
In summary, a series of novel thiazolidin-4-one derivatives 4a-b, 5a-b and 6-13 were designed, synthesized to evaluate their antimycobacterial activity. Among the target compounds, 6, 10 and 12 were found as most active compounds in the series. It was seen that both phenylamino and benzylidene substitutions on thiazolidin-4-one ring caused an improvement in the antimycobacterial activity.

References

  • 2.
    Huebner RE, Castro KG. The changing face of tuberculosis. Annu. Rev. Med. 1995;46:47-55. [PubMed ID: 7598480].
  • 3.
    Datta M, Radhamani MP, Selvaraj R, Paramasivan CN, Gopalan BN, Sudeendra CR, Prabhakar R. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. Tuber. Lung Dis. 1993;74:180-6. [PubMed ID: 8369512].
  • 4.
    Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin. Drug Saf. 2006;5:231-49. [PubMed ID: 16503745].
  • 5.
    Grundy WE, Whitman AL, Rdzok EG, Rdzok EJ, Hanes ME, Sylvester JC. Actithiazic acid 1 Microbiological studies. Antibiot. Chemother. 1952;2:399-408.
  • 6.
    Kucukguzel SG, Oruc EE, Rollas S, Sahin F, Ozbek A. Synthesis, characterisation and biological activity of novel 4-thiazolidinones, 1,3,4-oxadiazoles and some related compounds. Eur. J. Med. Chem. 2002;37:197-206. [PubMed ID: 11900864].
  • 7.
    Aridoss G, Amirthaganesan S, Kim MS, Kim JT, Jeong YT. Synthesis, spectral and biological evaluation of some new thiazolidinones and thiazoles based on t-3-alkyl-r-2,c-6-diarylpiperidin-4-ones. Eur. J. Med. Chem. 2009;44:4199-4210. [PubMed ID: 19535178].
  • 8.
    de Aquino TM, Liesen AP, da Silva REA, Lima VT, Carvalho CS, de Faria AR, de Araújo JM, de Lima JG, Alves AJ, de Melo EJT, Góes AJS. Synthesis, anti-Toxoplasma gondii and antimicrobial activities of benzaldehyde 4-phenyl-3-thiosemicarbazones and 2-[(phenylmethylene)hydrazono]-4-oxo-3-phenyl-5-thiazolidineacetic acids. Bioorg. Med. Chem. 2008;16:446-56. [PubMed ID: 17905587].
  • 9.
    Jaju S, Palkar M, Maddi V, Ronad P, Mamledesai S, Satyanarayana D, Ghatole M. Synthesis and antimycobacterial activity of a novel series of isonicotinylhydrazide derivatives. Arch. Pharm. 2009;342:723-31.
  • 10.
    Srivastava T, Gaikwad AK, Haq W, Sinha S, Katti SB. Synthesis and biological evaluation of 4-thiazolidinone derivatives as potential antimycobacterial agents. Arkivoc. 2005:120-30.
  • 11.
    Gupta P, Hameed S, Jain R. Ring-substituted imidazoles as a new class of anti-tuberculosis agents. Eur. J. Med. Chem. 2004;39:805-814. [PubMed ID: 15337293].
  • 12.
    Khan A, Sarkar S, Sarkar D. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages. Int. J. Antimicrob. Agents. 2008;32:40-5. [PubMed ID: 18538548].
  • 13.
    Li X, Manjunatha UH, Goodwin MB, Knox JE, Lipinski CA, Keller TH, Barry CE 3rd, Dowd CS. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo [2,1-b][1,3]oxazines, analogues of PA-824. Bioorg. Med. Chem. Lett. 2008;18:2256-62. [PubMed ID: 18358721].
  • 14.
    Pandey J, Tiwari VK, Verma SS, Chaturvedi V, Bhatnagar S, Sinha S, Gaikwad AN, Tripathi RP. Synthesis and antitubercular screening of imidazole derivatives. Eur. J. Med. Chem. 2009;44:3350-5. [PubMed ID: 19272678].
  • 15.
    Wilkinson BL, Bornaghi LF, Wright AD, Houston TA, Poulsen SA. Anti-mycobacterial activity of a bis-sulfonamide. Bioorg. Med. Chem. Lett. 2007;17(5):1355-7. [PubMed ID: 17258454].
  • 16.
    Gill C, Jadhav G, Shaikh M, Kale R, Ghawalkar A, Nagargoje D, Shiradkar M. Clubbed [1,2,3] triazoles by fluorine benzimidazole: a novel approach to H37Rv inhibitors as a potential treatment for tuberculosis. Bioorg. Med. Chem. Lett. 2008;18:6244-7. [PubMed ID: 18930654].
  • 17.
    Castagnolo D, Radi M, Dessi F, Manetti F, Saddi M, Meleddu R, De Logu A, Botta M. Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 2009;19:2203-5. [PubMed ID: 19299129].
  • 18.
    Turan-Zitouni G, Özdemir A, Asim Kaplancikli Z, Benkli K, Chevallet P, Akalin G. Synthesis and antituberculosis activity of new thiazolylhydrazone derivatives. Eur. J. Med. Chem. 2008;43:981-5. [PubMed ID: 17719146].
  • 19.
    Mallikarjuna BP, Sastry BS, Suresh Kumar GV, Rajendraprasad Y, Chandrashekar SM, Sathisha K. Synthesis of new 4-isopropylthiazole hydrazide analogs and some derived clubbed triazole, oxadiazole ring systems--a novel class of potential antibacterial, antifungal and antitubercular agents. Eur. J. Med. Chem. 2009;44:4739-46. [PubMed ID: 19589626].
  • 20.
    Mai A, Artico M, Esposito M, Ragno R, Sbardella G, Massa S. Synthesis and biological evaluation of enantiomerically pure pyrrolyl-oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors. Farmaco. 2003;58:231-41. [PubMed ID: 12620419].
  • 21.
    Mamolo MG, Zampieri D, Falagiani V, Vio L, Fermeglia M, Ferrone M, Pricl S, Banfi E, Scialino G. Antifungal and antimycobacterial activity of new N-1-[1-aryl-2-(1H-imidazol-1-yl and 1H-1,2,4-triazol-1-yl)-ethylidene]-pyridine-2-carboxamidrazone derivatives: a combined experimental and computational approach. Arkivoc. 2004:231-50.
  • 22.
    Castagnolo D, Manetti F, Radi M, Bechi B, Pagano M, De Logu A, Meleddu R, Saddi M, Botta M. Synthesis, biological evaluation, and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis: part 2 Synthesis of rigid pyrazolones. Bioorg. Med. Chem. 2009;17:5716-21. [PubMed ID: 19581099].
  • 23.
    Tangallapally RP, Sun D, Rakesh, Budha N, Lee RE, Lenaerts AJ, Meibohm B. Discovery of novel isoxazolines as anti-tuberculosis agents. Bioorg. Med. Chem.Lett. 2007;17:6638-42. [PubMed ID: 17937983].
  • 24.
    Mamolo MG, Zampieri D, Vio L, Fermeglia M, Ferrone M, Pricl S, Scialino G, Banfi E. Antimycobacterial activity of new 3-substituted 5-(pyridin-4-yl)-3H-1,3,4-oxadiazol-2-one and 2-thione derivatives Preliminary molecular modeling investigations. Bioorg. Med. Chem. 2005;13:3797-809. [PubMed ID: 15863006].
  • 25.
    Jain AK, Vaidya A, Ravichandran V, Kashaw SK, Agrawal RK. Recent developments and biological activities of thiazolidinone derivatives: A review. Bioorg. Med. Chem. 2012;20:3378-95. [PubMed ID: 22546204].
  • 26.
    Mečiarová M, Toma Š, Magdolen P. Ultrasound effect on the aromatic nucleophilic substitution reactions on some haloarenes. Ultrason. Sonochem. 2003;10:265-70. [PubMed ID: 12818392].
  • 27.
    Collins LA, Franzblau SG. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob. Agents Ch. 1997;41:1004-9.

Similar Articles

31
Mar
2015

Synthesis and Antimycobacterial Activity of some Triazole Derivatives–New Route to Functionalized Triazolopyridazines

Kamaleddin Haj Mohammad Ebrahim Tehrani,
Vida Mashayekhi,
Parisa Azerang,
Somayeh Minaei,
Soroush Sardari,
Farzad Kobarfard

Tehrani KHME, Mashayekhi V, Azerang P, Minaei S, Sardari S, et al. Synthesis and Antimycobacterial Activity of some Triazole Derivatives–New Route to Functionalized Triazolopyridazines. Iran J Pharm Res. 2015;14(Suppl):e125274. doi: https://doi.org/10.22037/ijpr.2015.1713

30
Apr
2013

Synthesis and Antimycobacterial Activity of Symmetric Thiocarbohydrazone Derivatives against Mycobacterium bovis BCG

Kamaleddin Haj Mohammad Ebrahim Tehrani,
Farzad Kobarfard,
Parisa Azerang,
Maryam Mehravar,
Zohreh Soleimani,
Ghazaleh Ghavami
,et al.

Haj Mohammad Ebrahim Tehrani K, Kobarfard F, Azerang P, Mehravar M, Soleimani Z, et al. Synthesis and Antimycobacterial Activity of Symmetric Thiocarbohydrazone Derivatives against Mycobacterium bovis BCG. Iran J Pharm Res. 2013;12(2):e125716. doi: https://doi.org/10.22037/ijpr.2013.1313

31
Oct
2011

Synthesis and Antimycobacterial Activity of 2-(Phenylthio) benzoylarylhydrazone Derivatives

Ali Almasirad,
Somayeh Samiee-Sadr,
Abbas Shafiee

Almasirad A, Samiee-Sadr S, Shafiee A. Synthesis and Antimycobacterial Activity of 2-(Phenylthio) benzoylarylhydrazone Derivatives. Iran J Pharm Res. 2011;10(4):e126007. doi: https://doi.org/10.22037/ijpr.2011.984

3
Jun
2022
Iran J Pharm Res

Synthesis, Structural Characterization, and Cytotoxic Activity of New Benzo[d]imidazo[2,1-b]thiazole Derivatives Against MCF-7 Breast Cancer Cells

Nahid Ahmadi,
Soraya Shahhosseini,
Farshad H Shirazi,
Golrokh Farnam,
Afshin Zarghi

Ahmadi N, Shahhosseini S, H Shirazi F, Farnam G, Zarghi A. Synthesis, Structural Characterization, and Cytotoxic Activity of New Benzo[d]imidazo[2,1-b]thiazole Derivatives Against MCF-7 Breast Cancer Cells. Iran J Pharm Res. 2022;21(1):e127041. doi: https://doi.org/10.5812/ijpr-127041

31
Oct
2015

Design, Synthesis and Evaluation of Antitubercular Activity of Novel Dihydropyridine Containing Imidazolyl Substituent

Maryam Iman,
Asghar Davood,
Golnoush Dehqani,
Mahboubeh Lotfinia,
Soroush Sardari,
Parisa Azerang
,et al.

Iman M, Davood A, Dehqani G, Lotfinia M, Sardari S, et al. Design, Synthesis and Evaluation of Antitubercular Activity of Novel Dihydropyridine Containing Imidazolyl Substituent. Iran J Pharm Res. 2015;14(4):e125381. doi: https://doi.org/10.22037/ijpr.2015.1744

Import into EndNoteImport into BibTex
Crossmark
Crossmark
Checking
Share on
Comments
Number of Comments:0
Cited by
Metrics
Licensing and reuse information

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC 

Search Relations

Author(s):

Related Articles

Related Article in PubMed

Related Article in Google Scholar

Create Citation Alert via Google Reader